Updated November 2, 2026

Wegovy Medicare GLP-1 Bridge: How to Get the $50 Copay

Evan Brown
Written by Evan Brown · Prescription Savings Researcher
Published July 28, 2026 · Updated November 2, 2026
How we wrote this: every program rule below comes from CMS's own Medicare GLP-1 Bridge pages and the Medicare.gov fact sheet, checked again on November 2, 2026. Sources are listed at the bottom. This is educational, not medical or legal advice.
Quick answer

The Medicare GLP-1 Bridge is a CMS demonstration that runs July 1, 2026 through December 31, 2027. If you're in an eligible Part D plan and Wegovy is prescribed for weight management, you pay a flat $50 for a 30-day supply. You don't sign up yourself. Your prescriber sends the prescription to your pharmacy, the pharmacy's claim to the Bridge triggers a prior authorization request, and your prescriber completes it. The $50 doesn't count toward your Part D out-of-pocket cap, and Extra Help doesn't lower it.

What's new as of November 2026

  • The Bridge now runs through 2027. CMS delayed the Part D side of its BALANCE model indefinitely and extended the Bridge to December 31, 2027. CMS has not announced what replaces it afterward.
  • Medicare open enrollment is open until December 7. The Part D out-of-pocket cap rises from $2,100 to $2,400 in 2027, and the standard deductible from $615 to $700. Neither applies to your $50 Bridge copay.
  • Wegovy prices are changing. Novo Nordisk has announced a US list price cut to $675 a month starting January 2027, and Wegovy is among the drugs with Medicare-negotiated prices starting January 1, 2027. Those prices affect Part D coverage and cash prices, not the Bridge's flat $50.
  • This article was corrected. The BMI and condition thresholds and the prior authorization steps now match CMS's published rules.

Key takeaways

  • The Bridge covers Wegovy (injection and tablets), the Zepbound KwikPen, and Foundayo, and only when prescribed for weight management. Ozempic is not included.
  • You can't apply directly. The pharmacy claim comes first, then your prescriber completes the prior authorization CMS sends them.
  • Type 2 diabetes, moderate-to-severe sleep apnea, and MASH (fatty liver with fibrosis) go through your regular Part D plan instead.
  • CMS says there is no formal appeals process. If you're denied, your prescriber corrects or adds information and resubmits.
  • Plan for the end date: nothing has been announced to replace the Bridge after December 31, 2027.

Medicare has never covered Wegovy for weight loss through the regular Part D benefit, because federal law excludes weight-loss drugs from it. The Bridge doesn't change that law. It builds a separate, temporary pathway around it: a flat $50 copay for a short list of GLP-1 drugs, paid and processed outside your Part D plan.

That's why it confuses people. You're still a Part D member, but your Bridge prescription follows different rules, a different approval path, and a different cost structure. AARP has reported that an estimated 3.8 million people with Part D could qualify.

What the Bridge covers

MedicationMakerIn the Bridge?
Wegovy (semaglutide), injection and tablets, all formulationsNovo NordiskYes
Zepbound (tirzepatide), KwikPen onlyEli LillyYes (vials and single-dose pens are not)
Foundayo (orforglipron), all formulationsEli LillyYes
Ozempic, Mounjaro (diabetes indications)Novo Nordisk / Eli LillyNo, covered by Part D for diabetes

Pen needles for the Zepbound KwikPen aren't covered by the Bridge, so you'd buy those separately.

Bridge or regular Part D?

The reason your prescriber writes Wegovy decides which pathway pays for it. CMS says a prescription written to reduce the risk of major cardiovascular events goes to your Part D plan, even if you'd also lose weight on it.

Medicare GLP-1 Bridge ($50)

  • Prescribed to reduce excess body weight and maintain weight loss
  • Paired with ongoing lifestyle changes (nutrition and activity)
  • You meet one of the BMI tiers below

Your regular Part D plan

  • Type 2 diabetes
  • Moderate-to-severe obstructive sleep apnea
  • MASH with moderate-to-advanced fibrosis
  • Prescribed to reduce major cardiovascular events (Wegovy)

Why this matters financially: spending through your Part D plan counts toward your annual out-of-pocket cap. The Bridge's $50 does not. If one of the conditions on the right applies to you, ask your prescriber to use Part D. Coverage depends on your plan's formulary and prior authorization rules.

Who qualifies

RequirementDetail
Age18 or older
Plan typeStandalone Part D plan, or a Medicare Advantage plan with drug coverage (HMO, HMOPOS, local or regional PPO). Special needs plans, employer group plans, and LI NET are also eligible. Private fee-for-service, cost, and PACE plans are not, unless you also have a standalone drug plan. People with Medicare and Medicaid can use the Bridge.
PurposePrescribed for weight management, with ongoing lifestyle modification
BMI tier 1BMI of 35 or higher
BMI tier 2BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension (above 140/90 despite two medications), or chronic kidney disease stage 3a or above
BMI tier 3BMI of 27 or higher with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease
Not eligibleType 2 diabetes, moderate-to-severe sleep apnea, or MASH, even if you otherwise meet the BMI tiers

BMI is measured when you started the drug, not when you apply. CMS's example: someone who started a GLP-1 at BMI 37 and is now at BMI 34 still meets the tier 1 criterion. That includes people who started before joining Part D or before July 1, 2026.

Your prescriber attests to all of this on the prior authorization form, under penalty of perjury. CMS may check claims such as a diabetes diagnosis against Medicare data.

How to get it, step by step

1

See a prescriber about weight management

Any prescriber can do this, and they don't have to be enrolled in Medicare (they just can't be on CMS's preclusion list). They decide whether Wegovy is right for you and document your BMI and any qualifying condition.

2

Confirm you're in an eligible Part D plan

Call 1-800-MEDICARE (1-800-633-4227) if you're unsure what plan type you have.

3

Your prescriber sends the prescription to your pharmacy first

The order matters. CMS says submitting the prior authorization before the pharmacy's first claim returns a "patient not found" error. A diagnosis code and a note to route the claim to the Bridge help but aren't required, and a Part D denial isn't needed first.

4

The pharmacy claim triggers a prior authorization request

The Bridge denies the first claim and tells the pharmacy a prior authorization is needed. The pharmacy sends the request to your prescriber by electronic prior authorization or fax, typically within 24 to 72 hours.

5

Your prescriber completes it

If nothing arrives after 72 hours, the prescriber can download CMS's fax form and submit it directly. Decisions come within 72 hours of submission, mailed to you and sent to the prescriber. The Bridge's central processor, which Humana runs under contract with CMS, handles this, not your Part D plan.

6

Fill the prescription and pay $50

Once approved, you pay $50 for a 30-day supply. Novo Nordisk says refills don't need a new prior authorization as long as you stay on the same GLP-1 medication.

At the pharmacy

  • Pharmacies don't have to opt in, so you don't need a special pharmacy or mail-order service.
  • The pharmacy bills the Bridge separately. Your other prescriptions still run through your Part D plan as usual.
  • You pay the $50 at the counter. There's nothing to file for reimbursement.
  • First fills are often rejected at first because the prior authorization isn't done yet. That's the process, not a pharmacy error. If the claim keeps failing, ask the pharmacist to confirm it's going to the Bridge rather than your Part D plan.

What the $50 does and doesn't do

FeatureBridgeRegular Part D
Who decidesCentral processorYour plan
Monthly costFlat $50 (doesn't rise with dose)Varies by plan and phase
Part D deductible appliesNoYes
Counts toward out-of-pocket cap ($2,100 in 2026, $2,400 in 2027)NoYes
Extra Help (low-income subsidy)NoYes, if you qualify
Weight-loss use of WegovyCovered if criteria are metExcluded by law
EndsDecember 31, 2027Ongoing

If you take another expensive drug and hit your Part D cap, you'll pay $0 for those drugs but still $50 a month for Wegovy. If you have Extra Help and normally pay a few dollars per prescription, $50 may be a real barrier. Coupons can't reduce the $50, either.

Example scenarios

These are illustrative, not real patients.

SituationLikely route
68-year-old, BMI 37, no diabetes, sleep apnea, or fatty liver disease; Wegovy prescribed for weight managementBridge, tier 1
72-year-old with prior heart attack, BMI 29; Wegovy prescribed to reduce cardiovascular eventsPart D plan (prescribed for heart risk). Weight-focused prescribing at BMI 27+ with a prior heart attack could fall under Bridge tier 3, so the stated purpose matters.
65-year-old with type 2 diabetes, BMI 38Not Bridge-eligible. Part D covers GLP-1s for diabetes.
Extra Help enrollee, BMI 36, usually pays under $12 per drugBridge works, but budget $50 a month. Extra Help doesn't apply.

After December 31, 2027

The Bridge was meant to be a six-month stopgap before CMS's BALANCE model launched in Part D in January 2027. Not enough drug plans signed up, so CMS delayed the Part D portion indefinitely and extended the Bridge through 2027. The Medicaid side of BALANCE is moving ahead separately in participating states.

The Bridge is a demonstration without statutory backing, and Congress hasn't changed the law excluding weight-loss drugs. KFF has noted Medicare beneficiaries could lose access in 2028 if nothing replaces it.

What to do now: treat December 31, 2027 as a real planning date. During open enrollment (through December 7), stay in an eligible plan type for 2027. Ask your prescriber well before late 2027 about alternatives, including whether a Part D-covered indication applies to you or whether a manufacturer cash-price program fits.

If you're denied

1

Find out who denied it and why

A Bridge prior authorization denial, a Part D plan rejection, and a pharmacy claim reject are different problems. Your denial letter and pharmacist can tell you which.

2

Check you're in the right lane

If you have type 2 diabetes, moderate-to-severe sleep apnea, or MASH, or Wegovy is for heart risk, use your Part D plan.

3

Have your prescriber resubmit

CMS says the Bridge has no appeals process. A prescriber can resubmit the form with corrected or additional information, such as BMI at therapy start or qualifying-condition documentation. Prescribers can call the Bridge call center at 855-273-0102, Monday to Friday, 8am to 7pm ET.

4

Get free help

Call 1-800-MEDICARE or your State Health Insurance Assistance Program (SHIP) for free, unbiased counseling. Novo Nordisk's patient support can also answer Wegovy-specific questions.

Common mistakes

  • Looking for a Bridge sign-up form. There isn't one.
  • Having the prescriber submit the prior authorization before the pharmacy has tried the claim.
  • Using the Bridge when a Part D indication (diabetes, sleep apnea, MASH, or heart risk) applies.
  • Sending the request to your Part D plan instead of the central processor.
  • Expecting the $50 to count toward your cap or be reduced by Extra Help or coupons.
  • Switching to an ineligible plan type during open enrollment.
  • Waiting until late 2027 to ask what comes next.

Frequently asked questions

A short-term CMS demonstration running July 1, 2026 through December 31, 2027. It lets eligible Part D enrollees get Wegovy, the Zepbound KwikPen, or Foundayo for weight management at a flat $50 monthly copay. It runs outside the Part D benefit through a central processor.

You must be 18 or older, be in an eligible Part D plan, and be prescribed Wegovy for weight management. You need a BMI of 35 or higher; or 30 or higher with certain heart failure, uncontrolled high blood pressure, or chronic kidney disease; or 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea, or MASH are not eligible.

No. Your prescriber sends the prescription to your pharmacy. The pharmacy's claim triggers a prior authorization request to your prescriber, who completes it. If approved, you pay $50 at the pharmacy.

No. The Part D deductible doesn't apply, none of the $50 counts toward your out-of-pocket costs (the cap is $2,100 in 2026 and $2,400 in 2027), and Extra Help doesn't reduce the copay.

No. The Bridge covers only Wegovy, the Zepbound KwikPen, and Foundayo, and only when prescribed for weight management. Ozempic is approved for type 2 diabetes, which Part D already covers.

The Bridge is scheduled to end December 31, 2027. CMS delayed the Part D portion of BALANCE indefinitely and hasn't announced a replacement, so $50 pricing after 2027 isn't guaranteed.

No. Pharmacies don't need to opt in. The pharmacy bills the central processor and collects your $50.

No. You must be in a standalone drug plan or a Medicare Advantage plan with drug coverage. Private fee-for-service, cost, and PACE plans aren't eligible unless you also have a standalone drug plan.

Sources

  1. CMS. Medicare GLP-1 Bridge (overview and FAQs).
  2. CMS. Medicare GLP-1 Bridge: Information for Providers (eligibility criteria, prior authorization process).
  3. Medicare.gov. Fact sheet: Medicare GLP-1 Bridge, GLP-1 Drugs for $50 a Month.
  4. KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge.
  5. NPR. Medicare launches weight loss drug option with $50 copay.
  6. Novo Nordisk. Wegovy is now accessible to eligible Medicare beneficiaries through the Medicare GLP-1 Bridge (July 1, 2026).
  7. AARP. Medicare $50 GLP-1 Weight Loss Bridge Program.

Editorial policy: Refill Relay researches content from public regulatory materials and manufacturer patient-support guidance, and updates articles when program rules change. Program details can change; confirm current rules with CMS, 1-800-MEDICARE, or your prescriber. This content is educational and is not medical or legal advice for your coverage.

Evan Brown
About the author
Evan Brown, Prescription Savings Researcher

Evan Brown researches prescription pricing and insurance mechanics and writes practical guidance for patients before they pay or run out.

View full profile →